fbpx
Loading...

ITTACc – ANZGOG’s latest cervical cancer study, incorporating ANZGOG’s first teletrial cluster!

A Phase II Trial of Tislelizumab in combination with Sitravatinib for Recurrent/Metastatic Cervical Cancer after Platinum-Based Chemotherapy. The ITTACc study is an ANZGOG-developed trial led in Australia by A/Prof Jeffrey Goh from the Royal [...]

ITTACc – ANZGOG’s latest cervical cancer study, incorporating ANZGOG’s first teletrial cluster!2023-10-18T11:49:12+11:00

ANZGOG’s Endometrial Cancer Study Awarded $1.27 Million in Funding from the MRFF Grant

ANZGOG’s TAPER Study has received $1.27 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) which aims to improve the health and wellbeing of Australians by supporting medical research and innovation.  [...]

ANZGOG’s Endometrial Cancer Study Awarded $1.27 Million in Funding from the MRFF Grant2023-10-18T11:50:42+11:00

Contributions of Five Outstanding Individuals Acknowledged in the 2023 ANZGOG Awards

The significant contributions of five exceptional individuals in improving outcomes for women diagnosed with gynaecological cancer were acknowledged during the conference dinner at the ANZGOG 2023 Annual Scientific Meeting held on 23 March, 2023. Join us [...]

Contributions of Five Outstanding Individuals Acknowledged in the 2023 ANZGOG Awards2023-10-18T11:51:21+11:00
Go to Top